The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. CTAF convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the CTAF process, and find out how topics are selected.

CTAF directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the CTAF Panel must meet ICER’s criteria for Conflict of Interest.

For CTAF reports published prior to September 2013, please email info@icer-review.org

The box below provides information on the topic of the next meeting of CTAF. For more information about past and other upcoming meetings, see the box to the right.


Next Meeting

October 25, 2018 10am-4pm PT

California Endowment Oakland Conference Center
2000 Franklin St.
Oakland, CA 94612

Hereditary Angioedema

CTAF will convene to review ICER's assessment of therapies for hereditary angioedema.


Hereditary Angioedema

ICER will assess the comparative clinical effectiveness and value of therapies for hereditary angioedema, a rare condition characterized by attacks of deep tissue swelling within the skin and/or mucosa. The report is expected to focus on four therapies for the prevention of hereditary angioedema attacks: lanadelumab (Shire), which is currently under review by the FDA with an approval decision expected in August of 2018, and three C1 esterase inhibitors (Haegarda®, CSL Behring; Cinryze®, Shire; and Ruconest®, Pharming). This list is tentative and subject to change.

View materials